{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:20:58Z","timestamp":1792704058337,"version":"4.5.0"},"reference-count":51,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T00:00:00Z","timestamp":1747872000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Journal of Scleroderma and Related Disorders"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>The use of Janus kinase inhibitors is increasing in systemic sclerosis, a complex autoimmune disease characterized by fibrosis, vasculopathy, and immune dysregulation. In this review, we aimed to examine the studies in the literature reporting on patients with systemic sclerosis treated with Janus kinase inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We performed a search on MEDLINE and Scopus for articles involving patients with systemic sclerosis treated with Janus kinase inhibitors from the inception of these databases through 1 August 2024.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Our literature search revealed 18 articles describing 87 systemic sclerosis patients treated with Janus kinase inhibitors. The median (min-max) age of these patients was 48.5 (13\u201378) years (F\/M\u2009=\u20094.9). The most commonly used Janus kinase inhibitors in systemic sclerosis were tofacitinib (82.8%), followed by baricitinib (13.8%). Janus kinase inhibitors were most commonly used to treat the combination of interstitial lung disease and skin involvement (44.9%), and the combination of gastrointestinal system and skin involvement (38.8%). Improvement rates with Janus kinase inhibitors were 87.5%, and 5.9% of patients on Janus kinase inhibitors relapsed. Adverse events were observed in 50% of systemic sclerosis patients treated with Janus kinase inhibitors. Various infections (21.1%) were the most common adverse event reported following Janus kinase inhibitor use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Although Janus kinase inhibitors seem to be very effective, especially in patients with systemic sclerosis who have resistant\/progressive skin disease, some side effects should not be ignored. Therefore, controlled clinical trials in larger populations are needed on Janus kinase inhibitors use in systemic sclerosis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/23971983251342697","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T01:47:52Z","timestamp":1747964872000},"page":"182-188","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis"],"prefix":"10.1136","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1564-8996","authenticated-orcid":false,"given":"Seher","family":"Sener","sequence":"first","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Ziya","family":"Sener","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Erasmus University Medical Center, Rotterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ezgi Deniz","family":"Batu","sequence":"additional","affiliation":[{"name":"Division of Pediatric Rheumatology, Department of Pediatrics, Hacettepe University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alper","family":"Sari","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Ankara Etlik State Research and Training Hospital, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Akdogan","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"issue":"11","key":"e_1_3_2_2_2","first-page":"1050","article-title":"An overview of systemic sclerosis","volume":"5","author":"Xhaferi E","year":"2016","unstructured":"Xhaferi E, Lamaj F. An overview of systemic sclerosis. IJSR 2016; 5(11): 1050\u20131062.","journal-title":"IJSR"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-010-8198-y"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0302-6"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397198320915042"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpmed.2009.10.014"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-019-0184-z"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.31.1.100"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0270"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2022.103168"},{"key":"e_1_3_2_11_2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021; 372: n71.","journal-title":"BMJ"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa613"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1080\/08820139.2023.2222746"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10238-021-00745-5"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.explore.2022.06.001"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/20587392211036813"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1294496"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207767"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.31138\/mjr.34.2.266"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.532177"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1080\/03009742.2017.1387673"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac031"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.159566"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-021-04956-7"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06660-2"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae206"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.859330"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40744-019-00181-8"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14876"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.15-6-s58"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-017-8636-1"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13026"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102403"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04565-w"},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-021-08891-0"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2019.1704125"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40674-018-0102-6"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209909"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.12164"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/2397198319865367"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/cei.13238"},{"key":"e_1_3_2_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.34500"},{"key":"e_1_3_2_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102390"},{"key":"e_1_3_2_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2020.114103"},{"key":"e_1_3_2_45_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0701-9"},{"issue":"1","key":"e_1_3_2_46_2","first-page":"4","article-title":"Targeting cytokines and potentiality of JAK\u2013STAT inhibition in systemic sclerosis","volume":"6","author":"Aung WW","year":"2023","unstructured":"Aung WW, Hamaguchi Y, Matsushita T. Targeting cytokines and potentiality of JAK\u2013STAT inhibition in systemic sclerosis. JCIA 2023; 6(1): 4\u201312.","journal-title":"JCIA"},{"key":"e_1_3_2_47_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.211393"},{"key":"e_1_3_2_48_2","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000896"},{"key":"e_1_3_2_49_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-10777-w"},{"issue":"1","key":"e_1_3_2_50_2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/ddg.14668","article-title":"JAK-inhibitors in dermatology\u2014small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects","volume":"20","author":"Klein B","year":"2022","unstructured":"Klein B, Treudler R, Simon JC. JAK-inhibitors in dermatology\u2014small molecules, big impact? Overview of the mechanism of action, previous study results and potential adverse effects. J Dtsch Dermatol Ges 2022; 20(1): 19\u201324.","journal-title":"J Dtsch Dermatol Ges"},{"key":"e_1_3_2_51_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.41580"},{"key":"e_1_3_2_52_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2017.51"}],"container-title":["Journal of Scleroderma and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23971983251342697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/23971983251342697","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/23971983251342697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T11:53:03Z","timestamp":1777981983000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/23971983251342697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":51,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1177\/23971983251342697"],"URL":"https:\/\/doi.org\/10.1177\/23971983251342697","relation":{},"ISSN":["2397-1983","2397-1991"],"issn-type":[{"value":"2397-1983","type":"print"},{"value":"2397-1991","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}